Daiwa Securities Group Inc. Purchases 41 Shares of argenx SE (NASDAQ:ARGX)

Daiwa Securities Group Inc. lifted its holdings in argenx SE (NASDAQ:ARGX) by 2.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,530 shares of the company’s stock after buying an additional 41 shares during the period. Daiwa Securities Group Inc.’s holdings in argenx were worth $582,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Parkside Financial Bank & Trust purchased a new position in argenx in the third quarter worth $28,000. FNY Investment Advisers LLC purchased a new position in shares of argenx in the 4th quarter worth about $38,000. Nkcfo LLC grew its position in argenx by 22.1% during the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after buying an additional 21 shares during the period. CWM LLC increased its holdings in argenx by 29.4% during the third quarter. CWM LLC now owns 207 shares of the company’s stock worth $102,000 after buying an additional 47 shares during the last quarter. Finally, Toronto Dominion Bank raised its position in argenx by 174.2% in the third quarter. Toronto Dominion Bank now owns 266 shares of the company’s stock worth $131,000 after acquiring an additional 169 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $368.60 on Friday. The firm has a fifty day moving average price of $386.41 and a two-hundred day moving average price of $418.17. The company has a market cap of $21.91 billion, a price-to-earnings ratio of -71.71 and a beta of 0.65. argenx SE has a one year low of $327.73 and a one year high of $550.76.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The business had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the prior year, the business posted ($0.70) EPS. Equities research analysts expect that argenx SE will post -2.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Robert W. Baird reduced their target price on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Truist Financial raised their target price on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Scotiabank upped their price target on argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $451.00 price objective on shares of argenx in a report on Thursday, April 18th. Finally, Piper Sandler boosted their price objective on argenx from $518.00 to $522.00 and gave the company an “overweight” rating in a research note on Friday, January 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $528.16.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.